AgingOpportunities.com
e-News and Information for Geriatricians and Gerontologists

Breaking News Stories

New Vaccine Can Protect Older Adults from Shingles

Did you know…
There is a relatively new vaccine -- Zostavax (“Zos-tah-vax”) -- that can lower the risk of getting shingles. Shingles is an extremely painful and debilitating rash that can lead to even more severe complications. The Centers for Disease Control and Prevention recommends the vaccine for most adults age 60 or older.

The disease known as shingles (also called herpes zoster) occurs when the varicella-zoster virus (VZV) -- the same virus that causes chickenpox -- is reactivated in the body. Like all herpes viruses, VZV remains in the body for life, even after a child recovers from chickenpox. As a person’s immunity to VZV begins to decline at the cellular level at older ages, the VZV virus can travel back up the nerve and reach the skin, causing the painful rash known as shingles. The blistering rash is usually limited to a small area on one side of the body, often on the face or torso. Shingles also can produce typical virus symptoms: chills, fever, upset stomach or headache.

Starting anti-viral medication within 72 hours of the onset of shingles can reduce the pain and the length of time the outbreak lasts. Anti-viral medicines used to treat shingles include acyclovir (Zovirax), famciclovir (Famvir) and valacyclovir (Valtrex). The disease runs its course in three or four weeks.

However, complications such as a chronic pain syndrome develop in somewhere between one-third and one-half of older adults with shingles.  These complications can make it difficult to sleep, leave the house or shop. Sometimes the person is never able to return to normal activities, and becomes depressed and reclusive because of long-term pain and disability. “Shingles can really blight the lives of older people,” commented Michael Oxman, MD, Study Chairman of the Department of Veterans Affairs’ (VA) Shingles Prevention Study and Professor of Medicine and Pathology,
University of California, San Diego and Staff Physician (Infectious Diseases) at the VA San Diego Healthcare System. “I have seen active people end up in a nursing home due to PHN,” he said.

The most frequent complication is the chronic pain syndrome called postherpetic neuralgia (PHN). PHN is the occurrence of persistent pain after the shingles rash heals; it can last for months or even years. The long-term pain of PHN exceeds pain scores for childbirth, musculoskeletal pain, osteoarthritis and chronic cancer pain, research has shown.

In addition to the excruciating pain of PHN, other complications of shingles may include scarring, secondary bacterial infections, pneumonia, visual and hearing impairments and, rarely, death. If left untreated, 10% of patients whose shingles affects an eye will experience severe visual loss, eyelid scarring or chronic in-turning of the eyelashes.

Older adults are more likely than younger adults to have a more severe case of shingles and to develop PHN.

Topical antibiotics may be prescribed if the blisters become infected. A medicated lotion (such as Benadryl or Caladryl) or astringent soaks (such as Bluboro or Domeboro) may relieve pain and itching, according to the
American Academy of Family Physicians. Pain medicine (analgesics or opioids) also may be prescribed for shingles or PHN.

Fortunately, researchers have developed a preventive vaccine, Zostavax, sold by Merck. Zostavax is a live, attenuated vaccine, meaning it is a living organism that has been weakened and adapted to provide immunity without causing illness. Researchers believe the vaccine works by boosting VZV-specific immunity. Zostavax is a stronger version of the same varicella vaccine that is given to children to prevent chicken pox. It is important to point out that the vaccine is for preventing, not treating, shingles.

Approved by the FDA in May 2006, Zostavax is licensed as a one-dose vaccine for people age 60 years or older. The federal Advisory Committee on Immunization Practices (ACIP), an advisory body to CDC, voted in October 2006 to recommend the vaccine. Those recommendations will be published shortly in Morbidity and Mortality Weekly Report.

Based on the findings of the Shingles Prevention Study, a large clinical trial that tested Zostavax versus placebo in 38,000 adults who were age 60 years or older, the vaccine reduced:

The study also found that the vaccine’s effectiveness in reducing the incidence of shingles drops with the age of the vaccine recipient. For example, Zostavax was 64% effective for those age 60-69 years, 41% effective for those ages 70-79 years and 18% effective for those age 80 years or older. However, the number of cases of shingles and PHN among people age 80 or older is so high that vaccinating this population actually has major impact, according to CDC. Considering how severely shingles can impact people, and the vaccine’s reduction of the risk of developing PHN, this is considered an important vaccine for older adults of all ages.

“The vaccine is more effective in people ages 60-69, so it is probably better that they get vaccinated at that age,” said Megan Lindley, MPH, coordinator of the Shingles Vaccine Implementation Group in CDC’s Immunization Services Division. “Although it is not 100% effective, shingles is so common that having people vaccinated against the disease should have a profound effect on public health.”

There are no contraindications for most older people with existing chronic disease who may be taking medications. However, the vaccine should not be given to people who have immunodeficiencies due to AIDS, leukemia, lymphoma or malignant neoplasms affecting the bone marrow or lymphatic system.

As with most vaccines, common side effects include mild reactions (discomfort, swelling or redness) at the injection site, headache or itching. No serious problems have been identified from the shingles vaccine, CDC said.

Physician administration fees and other charges can bring the price for consumers to somewhere between $165 and $300 per vaccination. That is substantially more than older adults are used to paying for an influenza or pneumococcal vaccine. Adult vaccine costs are approximately $11 to $15 for influenza, $24 for pneumococcus, $180 for the three-dose series of hepatitis B, $120 for the two-dose series of hepatitis A and $134 for the two-dose series of varicella.

Starting in 2008, Congress required all Medicare Part D prescription drug plans, which are administered by private contractors, to include all commercially available vaccines not covered by Part B (which covers influenza and pneumococcal vaccines). However, Part D participants may have to meet a plan’s requirement for deductibles or copayments, and coverage may vary depending on what stage of prescription drug coverage (initial coverage period, gap or “donut hole,” catastrophic coverage) they are in. Starting in 2008, vaccine administration fees also are covered under Part D.

MedPAC, an independent federal body that advises Congress on Medicare issues, has suggested that Congress should permit coverage for appropriate preventive vaccines under Medicare Part B instead of Part D. “If beneficiaries have to pay the full payment rate for vaccines and then seek reimbursement from their plans, physicians are concerned that the out-of-pocket cost will discourage beneficiaries from seeking preventive care,” MedPAC told Congress in 2007. Putting all vaccines under Part B would increase Medicare spending “by less than $50 million for one year and by less than $1 billion over five years,” according to MedPAC’s data.

Ongoing research will determine future policy decisions, such as possibly lowering the recommended age for vaccination to 50, providing a “booster shot” at some later time after the initial vaccination, using a higher dose of vaccine or allowing vaccination of people with some degree of immunosuppression.

RESOURCES
Age Page: Shingles, http://www.niapublications.org/agepages/shingles.asp
CDC Vaccines & Immunizations website, http://www.cdc.gov/vaccines/
Herpes Zoster Vaccine Q&A (Shingles), http://www.cdc.gov/vaccines/vpd-vac/shingles/vac-faqs.htm
Immunization Action Coalition, http://www.immunize.org/zoster/
Merck shingles website, http://www.shinglesinfo.com/
Merck Vaccine Reimbursement Support Center, 800-REIMBVAX, http://www.vaccinesupportservices.com
Merck Zostavax website, http://zostavax.com/
National Network for Immunization Information shingles vaccine information, http://www.immunizationinfo.org/vaccineInfo/vaccine_detail.cfv?id=54
Partnership for Prevention, http://www.prevent.org/content/view/106/54
Patient Information about Zostavax, http://www.fda.gov/cber/label/zosmer052506pi.pdf
Shingles (Herpes Zoster) Vaccination, http://www.cdc.gov/vaccines/vpd-vac/shingles/default.htm#patient
Shingles (Medline Plus), http://www.nlm.nih.gov/medlineplus/shingles.html
Shingles (National Institutes of Health), http://nihseniorhealth.gov/shingles/toc.html
Shingles (Zoster): Questions and Answers: Information about the Disease and Vaccine, http://www.immunize.org/catg.d/p4221.pdf
Shingles Disease - Questions and Answers (Herpes Zoster), http://www.cdc.gov/vaccines/vpd-vac/shingles/dis-faqs.htm
Shingles Interactive Tutorial, http://www.nlm.nih.gov/medlineplus/tutorials/shingles/htm/index.htm
Shingles Vaccine: What You Need to Know, http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-shingles.pdf
Shingles: Hope through Research, http://www.ninds.nih.gov/disorders/shingles/detail_shingles.htm#96673223
Shingles: What Is Shingles, and Who Can Get It?, American Academy of Family Physicians, http://familydoctor.org/online/famdocen/home/common/infections/common/viral/574.html
Spotlight on Shingles: Know What You Can Do, www.spotlightonshingles.com
Zostavax Questions and Answers, http://www.fda.gov/Cber/products/zosmer052506qa.htm
Zoster (Shingles) Vaccine, http://www.cdc.gov/vaccines/recs/adult-specinfo.htm#zoster

###







Go to our Home Page

© AgingOpportunities Information Services 2008

Go to our Home Page